Regeneron Pharmaceuticals REGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.92B+4.0% | $14.34B+0.7% | $14.25B+0.2% | $14.21B+0.9% | $14.09B-0.8% | ||
| —— | —— | —— | —— | —— | ||
| $6.07B+3.7% | $5.85B+3.8% | $5.64B+3.7% | $5.43B+4.3% | $5.21B+1.5% | ||
| $2.71B+0.5% | $2.7B-0.6% | $2.72B-2.0% | $2.77B-4.3% | $2.9B-1.9% | ||
| $11.29B+4.9% | $10.77B+1.9% | $10.56B+1.8% | $10.37B+1.2% | $10.25B+0.4% | ||
| $3.63B+1.4% | $3.58B-3.0% | $3.69B-4.0% | $3.84B+0.3% | $3.83B-4.0% | ||
| 24.3%-0.6pp | 24.9%-0.9pp | 25.9%-1.1pp | 27%-0.2pp | 27.2%-0.9pp | ||
| $48M+9.6% | $43.8M+4.0% | $42.1M+15.0% | $36.6M-23.4% | $47.8M-13.4% | ||
| $1.53B-7.6% | $1.65B+11.0% | $1.49B+39.7% | $1.07B-10.1% | $1.19B+44.3% | ||
| $5.16B-1.4% | $5.23B+1.7% | $5.15B+5.5% | $4.87B-2.2% | $4.98B+4.3% | ||
| $733.5M+1.1% | $725.8M+28.0% | $567.1M+36.3% | $416.2M-14.2% | $484.9M+32.0% | ||
| $4.42B-1.8% | $4.5B-1.6% | $4.58B+2.7% | $4.46B-0.9% | $4.5B+2.0% | ||
| 29.6%-1.8pp | 31.4%-0.7pp | 32.1%+0.8pp | 31.4%-0.6pp | 31.9%+0.9pp | ||
| $41.05-1.3% | $41.57-0.6% | $41.81+5.2% | $39.73+1.0% | $39.33+2.6% | ||
| $4.17B+1.2% | $4.12B-2.2% | $4.21B-3.2% | $4.35B+0.6% | $4.33B-3.3% | ||
| 27.9%-0.8pp | 28.7%-0.8pp | 29.6%-1.0pp | 30.6%-0.1pp | 30.7%-0.8pp | ||
| $3.63B+1.4% | $3.58B-3.0% | $3.69B-4.0% | $3.84B+0.3% | $3.83B-4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regeneron Pharmaceuticals's revenue?
- Regeneron Pharmaceuticals (REGN) generated $14.9B in revenue over the trailing twelve months, up 5.9% year over year.
- Is Regeneron Pharmaceuticals profitable?
- Regeneron Pharmaceuticals reported $4.4B in net income over the trailing twelve months, a 29.6% net margin.
- What are Regeneron Pharmaceuticals's profit margins?
- Gross margin is 93.9% and operating margin is 24.3%, with a 29.6% net margin.
- What is Regeneron Pharmaceuticals's earnings per share?
- Regeneron Pharmaceuticals's diluted EPS over the trailing twelve months is $41.05.
- Where does Regeneron Pharmaceuticals's income statement data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
